"Anti-Obesity Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.
| Descriptor ID |
D019440
|
| MeSH Number(s) |
D27.505.954.427.140
|
| Concept/Terms |
Anti-Obesity Agents- Anti-Obesity Agents
- Agents, Anti-Obesity
- Anti Obesity Agents
- Anti-Obesity Drugs
- Anti Obesity Drugs
- Drugs, Anti-Obesity
- Antiobesity Drugs
- Drugs, Antiobesity
- Antiobesity Agents
- Agents, Antiobesity
Weight-Loss Agents- Weight-Loss Agents
- Agents, Weight-Loss
- Weight Loss Agents
- Weight-Loss Drugs
- Drugs, Weight-Loss
- Weight Loss Drugs
|
Below are MeSH descriptors whose meaning is more general than "Anti-Obesity Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Obesity Agents".
This graph shows the total number of publications written about "Anti-Obesity Agents" by people in this website by year, and whether "Anti-Obesity Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 2 | 4 |
| 2007 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 3 | 0 | 3 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Obesity Agents" by people in Profiles.
-
Updates in pharmacotherapy of obesity. J Natl Med Assoc. 2024 Oct; 116(5):576-587.
-
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity? Curr Cardiol Rep. 2024 Sep; 26(9):1011-1019.
-
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022 11; 163(5):1198-1225.
-
Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. J Card Fail. 2019 May; 25(5):380-400.
-
Changes in Pain Sensitization After Bariatric?Surgery. Arthritis Care Res (Hoboken). 2018 10; 70(10):1525-1528.
-
Maternal Use of Weight Loss Products and the Risk of Neural Tube Defects in Offspring: A Systematic Literature Review. Birth Defects Res. 2018 01 15; 110(1):48-55.
-
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clin Obes. 2016 Oct; 6(5):305-12.
-
Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents. Best Pract Res Clin Endocrinol Metab. 2016 06; 30(3):357-71.
-
Comprehensive Map of Molecules Implicated in Obesity. PLoS One. 2016; 11(2):e0146759.
-
Gastrointestinal Conditions in the Obese Patient. Adolesc Med State Art Rev. 2016; 27(1):93-108.